Diego A. Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology and Medical Oncologist at Angeles del Carmen Hospital, shared a post on X:
“Izalontamab brengitecan in actionable NSCLC. Phase Ib iza-bren showed activity across actionable NSCLC alterations beyond classical EGFR mutations:
- ORR 39.7%, DCR 85.9%, median PFS 7.0 mo
- EGFR exon20ins/nonclassical EGFR: ORR 69.2%, PFS 10.5 mo
- HER2-mutant: ORR 52.9%, PFS 7.5 mo
Relevant hematologic toxicity, but manageable safety profile overall.”
Title: Izalontamab Brengitecan in Locally Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study
Authors: Huaqiang Zhou, Hongyun Zhao, Xue Hou, Yongsheng Wang, Zhiyong He, Yongsheng Li, Yuxiang Ma, Yuanyuan Zhao, Yan Huang, Likun Chen, Sa Xiao, Hai Zhu, Yi Zhu, Wenfeng Fang, Li Zhang, Yunpeng Yang
Read the Full Article.
Tumor-Naïve ctDNA Testing May Refine Risk in Early-Stage NSCLC 
